Literature DB >> 10777098

Molecular characterization and applications of recombinant scFv antibodies to CD152 co-stimulatory molecule.

M P Pistillo1, P L Tazzari, J H Ellis, G B Ferrara.   

Abstract

Recombinant human monoclonal antibodies against CD152 have been generated by selecting a synthetic phage scFv library with purified CD152-Ig fusion protein. Sixteen scFv fragments were isolated which specifically react with CD152 by enzyme-linked immunoabsorbent assay (ELISA) and Western blot resulting in their clustering into two groups recognizing different antigenic determinants. One group of scFvs (#3, #13, #40, #44, #47, #51, #57, #80 #83) recognized an epitope on CD152 dimer whereas another group (#15, #18, #31, #35, #54, #72, #81) recognized an epitope on both dimeric and monomeric CD152 molecule suggesting their possible use in understanding the subunit structure of CD152 which is still controversial. Sequencing of the VH genes revealed that all the scFvs belonged to the VH3 gene family but they were different in CDR3 length and composition. It was possible to correlate specific CDR3 sequences with reactivity of the two groups of scFvs. Four scFvs, #3, #40, #81 and #83, each representative of one specific CDR3, were selected for further analysis. Competition ELISA experiments showed that they recognize CD152 in its native configuration and bound to different epitopes from the CD80/CD86 interaction site. The scFvs were able to stain human T lymphocytes stimulated either with anti-CD3 and CD28 antibodies or PHA, PMA and ionomycin by cytofluorimetry suggesting that they can be useful reagents for monitoring the kinetics of surface-bound and intracellular CD152.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10777098     DOI: 10.1034/j.1399-0039.2000.550306.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  3 in total

1.  Depleting syndecan-4+ T lymphocytes using toxin-bearing dendritic cell-associated heparan sulfate proteoglycan-dependent integrin ligand: a new opportunity for treating activated T cell-driven disease.

Authors:  Hideo Akiyoshi; Jin-Sung Chung; Mizuki Tomihari; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  J Immunol       Date:  2010-02-22       Impact factor: 5.422

2.  Expression of CTLA-4 in nonhuman primate lymphocytes and its use as a potential target for specific immunotoxin-mediated apoptosis: results of in vitro studies.

Authors:  G L Palmisano; P L Tazzari; E Cozzi; A Bolognesi; L Polito; M Seveso; E Ancona; F Ricci; R Conte; F Stirpe; G B Ferrara; M P Pistillo
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

3.  Site-directed in vitro immunization leads to a complete human monoclonal IgG4 lambda that binds specifically to the CDR2 region of CTLA-4 (CD152) without interfering the engagement of natural ligands.

Authors:  Li-Te Chin; Chishih Chu; Han-Min Chen; Shu-Ching Hsu; Bor-Chun Weng; Chi-Hong Chu
Journal:  BMC Biotechnol       Date:  2007-08-23       Impact factor: 2.563

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.